glp 1 in type 1 diabetes GLP-1 for Weight Loss and Glucagon-like peptide-1 (GLP-1) receptor agonists

Description

Drugs which are GLP-1 receptor agonists or DPP-4 inhibitors are shown in Table 1

This may relate to the role of amylin as a regulator of body mass but could also be a manifestation of the increased beta cell secretory activity often found in obesity

We expect to see more pack trade-offs in potato chips, soft drinks and cold cereal but we also see outsized pack trade-offs in coffee and granola, which implies two emerging trends in the GLP-1 population: a general decrease in snacking, even for snacks usually considered healthy, and overall collateral damage that is spreading to categories that should not be greatly affected by GLP-1 status. In addition to their impact on the retail food and beverage market, oral GLP-1 medications are expected to account for 20% of total GLP-1 drug sales by 2031, with a pill market that is estimated to grow from $3.2 billion in 2025 to $34.3 billion in 2031, according to GlobalData.